Bone marrow fibrosis is a central pathological feature and World Health Organization major
diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of …

Abstract The 2001/2008 World Health Organization (WHO)-based diagnostic criteria for
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) …

Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …

Background Primary analyses of cohort 1a of the REFINE trial showed that addition of
navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR 35) and …

T-cell acute lymphoblastic leukemia is caused by the accumulation of multiple oncogenic
lesions, including chromosomal rearrangements and mutations. To determine the frequency …

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm characterized by
clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines …

JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and
is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the …

Fibrosis contributes to the development of many diseases and many target molecules are
involved in fibrosis. Currently, the majority of fibrosis treatment strategies are limited to …

There has been a major revolution in the management of patients with myeloproliferative
neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly …

Background Myelofibrosis (MF) is a life-shortening complication of myeloproliferative
neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone …